MCM
SANA icon

Manchester Capital Management’s Sana Biotechnology SANA Stock Holding History

Manchester Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300
Closed -$7K – 1093
2021
Q3 		$7K Buy
+300
New +$6.3K ﹤0.01% 639

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Manchester Capital Management's SANA Position: Q4 2021 in Review

Manchester Capital Management sold out of Sana Biotechnology (SANA) in Q4 2021, closing a stake of 300 shares — an estimated $7K sold.

Manchester Capital Management first reported a position in SANA in Q3 2021 and held it in 1 quarter. The position peaked at $7K in Q3 2021. 105 funds tracked by Wall St. Rank hold SANA as of Q4 2021.

  • Manchester Capital Management reported no remaining Sana Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Manchester Capital Management sold 300 Sana Biotechnology shares in Q4 2021, an estimated $7K.
  • Manchester Capital Management first reported a position in Sana Biotechnology in Q3 2021 and held it in 1 quarter.
  • Manchester Capital Management's Sana Biotechnology position peaked at $7K in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2021.

Based on Manchester Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.